L.T. BAYAZITOVA^{1, 2}, A.A. SHAYAKHMETOVA², M.N. BELOVA³, R.I. ANAMOV²

 ¹Kazan Scientific Research Institute of Epidemiology and Microbiology, Kazan

²Kazan State Medical University, Kazan

³Republic Clinical Hospital for Infectious Diseases named after Prof. A.F. Agafonov, Kazan

⁴Aibolit Medical center, Kazan⁵Russian National Research Medical University named after N.I. Pirogov, Moscow

Contact details:

Bayazitova L.T. — PhD (Medicine), Leading Researcher, Head of the Microbiology Laboratory, Associate Professor of the Department of Microbiology named after Acad. V.M. Aristovskiy

Address: 67 Bolshaya Krasnaya St., 420015 Kazan, Russian Federation, tel.: +7-987-234-19-45, e-mail: bajalt@mail.ru

 Streptococcus pneumoniae is one of the main causative agents of community-acquired pneumonia of bacterial etiology. To ensure optimal clinical efficacy, it is important to choose antibacterial drugs for community-acquired pneumonia and other diseases of the lower respiratory tract. At the same time, it is necessary to take into account regional data on the profile of antibiotic resistance of etiologically important bacteria. The article presents the results of a study of the antibiotic sensitivity dynamics of Streptococcus pneumoniae isolated from the sputum of patients hospitalized in Kazan with chronic bronchopulmonary diseases. We found a decrease of beta-lactam-sensitive strains from 94.11 to 77.84% and of macrolide-sensitive strains from 74.28 to 64.97%. The share of strains sensitive to norfloxacin was 83.72–96.66%; sensitive to linezolid — 98.92–100.0%; sensitive to clindamycin — 80.0–90.42% of isolates. Low anti-pneumococcal activity of co-trimoxazole was revealed.

Key words: community-acquired pneumonia, antibiotic sensitivity, pneumococci, antimicrobial therapy.

REFERENCES

1. Avdeev S.N., Dekhnich A.V., Zaytsev A.A., Kozlov R.S., Rachina S.A., Rudnov V.A. et al. Community-acquired pneumonia: federal clinical guidelines for diagnosis and treatment. Pul’monologiya, 2022, vol. 32, no. 3, pp. 295–355 (in Russ.). DOI: 10.18093/0869-0189-2022-32-3-295-355
2. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2022 g.: Gosudarstvennyy doklad [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2022: State report]. Moscow: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, 2023. 368 p., available at: https://www.rospotrebnadzor.ru/upload/iblock/b50/t4kqksh4b12a2iwjnha29922vu7naki5/GD-SEB.pdf
3. Metodicheskie ukazaniya MU 3.1.2/4.2.3973-23 Federal’noy sluzhby po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka “Epidemiologicheskiy nadzor za vnebol’nichnymi pnevmoniyami” [Methodical instructions MU 3.1.2/4.2.3973-23 of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing «Epidemiological surveillance of community-acquired pneumonia»]. Moscow, 2024. 71 p.
4. Zakharenkov I.A., Rachina S.A., Dekhnich N.N., Kozlov R.S. et al. Etiology of severe community-acquired pneumonia in adults: results of the first Russian multicenter study. Terapevticheskiy arkhiv, 2020, no. 1 (in Russ.), available at: https://cyberleninka.ru/article/n/etiologiya-tyazheloy-vnebolnichnoy-pnevmonii-u-vzroslyh-rezultaty-pervogo-rossiyskogo-mnogotsentrovogo-issledovaniya (accessed: 23.08.2024).
5. Klinicheskie rekomendatsii MZ RF “Vnebol’nichnaya pnevmoniya u vzroslykh”, 2021 [Clinical guidelines of the Ministry of Health of the Russian Federation «Community-acquired pneumonia in adults», 2021], available at: https://spulmo.ru/upload/kr/Pneumonia_2021.pdf
6. Rachina S.A., Zakharenkov I.A., Dekhnich N.N., Kozlov R.S., Sinopal’nikov A.I., Arkhipenko M.V. et al. Practice of antibacterial therapy of severe community-acquired pneumonia in adults in multidisciplinary hospitals of Russia. Antibiotiki i Khimioterapiya, 2022, vol. 67, no. 1-2, pp. 16–23 (in Russ.). DOI: 10.37489/0235-2990-2022-67-1-2-16-23
7. Metodicheskie rekomendatsii MR 4.2.0114-16 “Laboratornaya diagnostika vnebol’nichnoy pnevmonii pnevmokokkovoy etiologii”. Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka [Methodical recommendations MR 4.2.0114-16 «Laboratory diagnostics of community-acquired pneumonia of pneumococcal etiology». Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing]. Moscow, 2016, available at: https://docs.cntd.ru/document/456092897
8. Rekomendatsii MAKMAKh ‘Opredelenie chuvstvitel’nosti mikroorganizmov k antimikrobnym preparatam”, 2024, [Recommendations of IACMA «Determination of the sensitivity of microorganisms to antimicrobial drugs», 2024], available at: https://www.antibiotic.ru/minzdrav/category/clinical-recommendations/
9. Frank E., Liu J., Kinasewitz G., Moran G.J., Oross M.P., Olson W.H. et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin. Ther, 2002, vol. 24 (8), pp. 1292–1308. DOI: 10.1016/s0149-2918(02)80034-0
10. Zaytsev A.A., Guchev I.A. Community-acquired pneumonia — tactics of antibacterial therapy after the COVID-19 pandemic. Consilium Medicum, 2023, vol. 25, no. 9, pp. 581–588 (in Russ.). DOI: 10.26442/20751753.2023.9.202408
11. Ivanchik N.V., Chagaryan A.N., Sukhorukova M.V. Antibiotic resistance of clinical strains of Streptococcus pneumoniae in Russia: results of the multicenter epidemiological study «Pegas 2014-2017». KMAKh, 2019, vol. 21, no. 3, pp. 230–237 (in Russ.). DOI: 10.36488/cmac.2019.3.230-237
12. Taube A.A., Demidova O.A., Aleksandrova T.V., Stepanov E.A., Zhuravleva M.V., Alyautdin R.N. Analysis of the structure of prescribing antibacterial drugs for community-acquired pneumonia in the context of clinical practice. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya, 2022, vol. 24, no. 4, pp. 388–394 (in Russ.). DOI: 10.36488/cmac.2022.4.388-394
13. Chuchalin A.G., Avdeev S.N., Aysanov Z.R., Belevskiy A.S., Leshchenko I.V., Ovcharenko S.I., Shmelev E.I. Chronic obstructive pulmonary disease: federal clinical guidelines for diagnosis and treatment. Pul’monologiya, 2022, vol. 32, no. 3, pp. 356–392 (in Russ.). DOI: 10.18093/0869-0189-2022-32-3-356-392
14. Sinopal’nikov A.I., Zaytsev A.A. «Respiratory» fluoroquinolones in the treatment of community-acquired pneumonia in adults: rationale for choice. Consilium Medicum, 2008, vol. 10, no. 3, pp. 28–34 (in Russ.), available at: https://consilium.orscience.ru/2075-1753/article/view/92592
15. Lüthi-Corridori G., Roth A.I., Boesing M., Jaun F., Tarr Ph.E., Leuppi-Taegtmeyer A.B., Leuppi J.D. Diagnosis and therapy of community-acquired pneumonia in the emergency department: a retrospective observational study and medical audit. J. Clin. Med, 2024, vol. 13 (2), p. 574. DOI: 10.3390/jcm13020574
16. Metlay J.P., Waterer G.W., Long A.C. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America, available at: https://doi.org/10.1164/rccm.201908-1581ST
17. Shakeel S., Muneswarao J., Abdul Aziz A., Le H.Y., Abd Halim F.S. et al. Adherence to National antimicrobial guidelines in hospitalized geriatric patients with community-acquired pneumonia: a prospective observational study in a Malaysian hospital. DOI: 10.3390/antibiotics10121490
18. Kozlov R.S., Murav’ev A.A., Chagarina A.N. Epidemiology and antibiotic resistance of S. pneumoniae serotypes circulating in the adult population in the Russian Federation (SPECTRUM study). KMAKh, 2021, vol. 23, no. 2, pp. 127–137 (in Russ.). DOI: 10.36488/cmac.2021.2.127-137